NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.

Published

Journal Article

Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thrombohemorrhagic complications and a high risk of transformation to MF and acute myeloid leukemia. The diagnosis and management of PV and ET has evolved since the identification of mutations implicated in their pathogenesis. These NCCN Guideline Insights discuss the recommendations outlined in the NCCN Guidelines for the risk stratification, treatment, and special considerations for the management of PV and ET.

Full Text

Duke Authors

Cited Authors

  • Mesa, RA; Jamieson, C; Bhatia, R; Deininger, MW; Fletcher, CD; Gerds, AT; Gojo, I; Gotlib, J; Gundabolu, K; Hobbs, G; McMahon, B; Mohan, SR; Oh, S; Padron, E; Papadantonakis, N; Pancari, P; Podoltsev, N; Rampal, R; Ranheim, E; Reddy, V; Rein, LAM; Scott, B; Snyder, DS; Stein, BL; Talpaz, M; Verstovsek, S; Wadleigh, M; Wang, ES; Bergman, MA; Gregory, KM; Sundar, H

Published Date

  • October 2017

Published In

Volume / Issue

  • 15 / 10

Start / End Page

  • 1193 - 1207

PubMed ID

  • 28982745

Pubmed Central ID

  • 28982745

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2017.0157

Language

  • eng

Conference Location

  • United States